Updated safety and efficacy results of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma Meeting Abstract
| Authors: | Vij, R.; Kumar, S. K.; D'Souza, A.; McKay, J. T.; Voorhees, P. M.; Chung, A.; Tuchman, S. A.; Korde, N.; Weisel, K.; Teipel, R.; Bueno, O.; Feng, Z.; Rosenberg, T. S.; Pothacamury, R. K.; Polepally, A. R.; Lee, S.; Jin, Z.; Ross, J. A.; Ahsan, A.; Talati, C.; Rodriguez, C. |
| Abstract Title: | Updated safety and efficacy results of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 3378 |
| Language: | English |
| ACCESSION: | WOS:001159740303241 |
| DOI: | 10.1182/blood-2023-182388 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
